Medexus Pharmaceuticals (TSE:MDP - Get Free Report) was upgraded by stock analysts at Leede Financial from a "moderate buy" rating to a "strong-buy" rating in a research report issued on Wednesday,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals' FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.
A number of other brokerages have also recently weighed in on MDP. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Stifel Nicolaus upped their price objective on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Finally, Raymond James raised Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Strong Buy" and an average price target of C$5.58.
Check Out Our Latest Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 4.2 %
MDP stock traded down C$0.20 during mid-day trading on Wednesday, hitting C$4.55. 230,532 shares of the company were exchanged, compared to its average volume of 132,217. The firm has a market capitalization of C$111.61 million, a P/E ratio of 91.00 and a beta of 1.96. The business has a fifty day simple moving average of C$3.14 and a 200-day simple moving average of C$2.69. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$5.56.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
